The Stephens group carries out research in synthetic organic chemistry with a focus on asymmetric synthesis and medicinal chemistry.
Dr Stephens’ interest in asymmetric synthesis lies in the efficient control of selectivity (enantio-, diastereo, regio-, and chemo-) in bond making reactions, particularly C-C bond making processes. The demand for new and economical asymmetric reactions is being driven by the pharmaceutical industry due to the chiral nature of many pharmaceutical products.
Medicinal chemistry involves the design, synthesis and development of new pharmaceutical drugs that are suitable for therapeutic use. Dr Stephens has a particular interest in diabetes, neurological disorders and microbial infections and is currently investigating new routes to novel chemical therapies.
Dr Stephens is also interested in the design, synthesis and application of novel fluorophores(fluorescent organic molecules) and investigating and elucidating biosynthetic pathways in microorganisms.
|Design, synthesis and evaluation of novel therapeutics for type 2 diabetes||Chemistry Department MU|
|New asymmetric organocatalytic methodologies.||Chemistry Department MU|
|New organic fluorophores and their potential application as organic probes in biomolecular systems.||Chemistry Department MU|
|The design, synthesis and evaluation of novel neurological therapeutics.||Chemistry Department MUPharmaceuticals|
|Anti-obesity therapeutics: Design, synthesis and evaluation.||Chemistry Department MUPharmaceuticals|